top of page

Overview of Proprietary Analytics

Overview.PNG

The Pharma Division of Deep Knowledge Analytics encompasses deep intelligence of the pharma industry and the AI for Drug Discovery sector. AI has already become the key ingredient of success for IT and Tech Corporations and is becoming crucially important for Pharma Corporations as well.This is why the knowledge and incorporation of AI and DL is of essential importance for the pharma corporations if they plan to maintain their positions and stay competitive. Deep industry analytics based on tangible, quantifiable metrics is crucial for big market players to become leaders, whereas for new players it is an opportunity to jump to the next stages.

 

The key questions regarding AI for Drug Discovery and Biomarker Development sector include:

  • What are the major threats and opportunities facing biopharma corporations regarding AI development in the industry?

  • What is the specifics of the stock indices aggregated based on pharma and tech corporations applying AI?

  • What are the main reasons for declining efficiency of R&D of biopharma corporations and what are business consequences and solutions for the corporations and other participants of the industry?

  • What are future prospects of pharma corporations regarding the evidence of R&D efficiency and how these prospects can be changed?

  • What are the major threats and opportunities facing investors in AI for Drug Discovery industry?

  • How can different institutions benefit from the aforementioned tendencies?

 

Currently Deep Knowledge Analytics Pharma Division has in pipeline 8 ongoing proprietary special case studies delivering practical answers and insights to these specific questions in order to optimize the short and long-term strategies of biopharma corporations and other entities related to the industry, with a newly updated edition being released each quarter, incrementally increasing the precision, practicality and actionability of its technological and financial analysis. Each new edition will provide a more sophisticated, comprehensive and precise understanding of the challenges and opportunities provided by the implementation of AI in Drug Discovery sector as well as what businesses such as pharma and tech corporations and private biotech companies need to do in order to benefit, rather than stagnate, from these tendencies.

 

Proprietary Analytical Reports will deliver:

 

  • Concrete deep analysis of the prospects of AI for Drug Discovery and Biomarker Development industry regarding the development of the different trends;

  • Tangible forecasts on the 3-5 years horizon, providing an overview of future scenarios of the development of AI in the pharma industry;

  • Practical guide to the optimized way for assembling the best possible tools and solutions to deal with the industry trends;

  • Quantifiable comparative/competitive analysis of key market players in the AI for Drug Discovery and Biomarker Development sector.

 

The parties who gain early access to these reports will have deep expertise on how their strategic agendas can be optimized and stabilized in order to manage the usage of AI for Drug Discovery and Biomarker Development, to surpass the challenges and to utilize the opportunities related to these novel biopharma trends.

​

bottom of page